- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–56
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 15
- States / cities
- San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
- Conditions
- Depressive Disorder, Major
- Interventions
- JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
- Conditions
- Depression, Dementia
- Interventions
- Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hot Flashes, Prostate Cancer
- Interventions
- oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
- Dietary Supplement · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 20
- States / cities
- Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
- Conditions
- Hot Flashes, Menopause, Vasomotor Disturbance
- Interventions
- Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 40 Years to 62 Years · Female only
- Enrollment
- 339 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more